why choose us

First received: April 22, 2023

Clinical Trial: Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Refractory Prostate Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study of M1774 in Refractory SPOP-Mutant Prostate Cancer

Brief Summary: This phase II trial tests how well M1774 works in treating patients with prostate cancer that does not respond to treatment (refractory) and that has a mutation in the gene responsible for making the speckle type BTB/POZ protein (SPOP).M1774 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.Giving M1774 may be able to shrink or stabilize refractory SPOP-mutant prostate cancer.

Read more